| Q43862483 | 5-HT(6) receptor antagonism potentiates the behavioral and neurochemical effects of amphetamine but not cocaine |
| Q37809899 | 5-HT6 Medicinal Chemistry |
| Q28287100 | 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease |
| Q46450693 | 5-HT6 receptor antagonists improve performance in an attentional set shifting task in rats |
| Q34138219 | 5-HT6 receptor binding sites in schizophrenia and following antipsychotic drug administration: autoradiographic studies with [125I]SB-258585. |
| Q28184669 | 5‐HT6 receptor antagonist SB‐271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex |
| Q46848285 | A null mutation of the serotonin 6 receptor alters acute responses to ethanol |
| Q38298172 | A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze. |
| Q37872282 | Advances in the design of 5-HT6 receptor ligands with therapeutic potential |
| Q44092155 | An RT-PCR study of 5-HT(6) and 5-HT(7) receptor mRNAs in the hippocampal formation and prefrontal cortex in schizophrenia. |
| Q34618354 | Biochemical and behavioral evidence for antidepressant-like effects of 5-HT6 receptor stimulation |
| Q45110152 | Biodistribution and radiation dosimetry of the serotonin 5-HT₆ ligand [¹¹C]GSK215083 determined from human whole-body PET. |
| Q50052167 | Characterization of Behavioral, Signaling and Cytokine Alterations in a Rat Neurodevelopmental Model for Schizophrenia, and Their Reversal by the 5-HT6 Receptor Antagonist SB-399885. |
| Q35042511 | Characterization of SB-271046: a potent, selective and orally active 5-HT(6) receptor antagonist |
| Q24674871 | Characterization of [(125)I]-SB-258585 binding to human recombinant and native 5-HT(6) receptors in rat, pig and human brain tissue |
| Q28646142 | Characterization of the 5-HT6 receptor coupled to Ca2+ signaling using an enabling chimeric G-protein |
| Q44491995 | Differential effects of iloperidone, clozapine, and haloperidol on working memory of rats in the delayed non-matching-to-position paradigm |
| Q44626972 | Differential involvement of 5-HT(1B/1D) and 5-HT6 receptors in cognitive and non-cognitive symptoms in Alzheimer's disease |
| Q83753521 | Distribution, level, pharmacology, regulation, and signaling of 5-HT6 receptors in rats and marmosets with special reference to an experimental model of parkinsonism |
| Q34111024 | E-6801, a 5-HT6 receptor agonist, improves recognition memory by combined modulation of cholinergic and glutamatergic neurotransmission in the rat. |
| Q24651957 | Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat |
| Q43913079 | Effects of the 5-HT(6) receptor antagonist, SB-271046, in animal models for schizophrenia |
| Q39158422 | Emerging chemical therapies targeting 5-hydroxytryptamine in the treatment of Alzheimer's disease |
| Q40621795 | Identification of a Potent and Selective 5-HT6Antagonist: One-Step Synthesis of (E)-3-(Benzenesulfonyl)-2- (methylsulfanyl)pyrido[1,2-a]pyrimidin- 4-ylidenamine from 2-(Benzenesulfonyl)-3,3- bis(methylsulfanyl)acrylonitrile |
| Q24675069 | In vivo effects of the 5-HT(6) antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate |
| Q35655182 | Neuropharmacological profile of aqueous extract of Anaphe venata larva (Notondotidae) in rats |
| Q28236198 | Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466 |
| Q34117799 | Pharmacological profile of SB-357134: a potent, selective, brain penetrant, and orally active 5-HT(6) receptor antagonist |
| Q42436868 | Potentiation of amphetamine-induced changes in dopamine and 5-HT by a 5-HT(6) receptor antagonist |
| Q43263890 | Protease-activated receptor-2 (PAR-2) in the rat gastric mucosa: immunolocalization and facilitation of pepsin/pepsinogen secretion |
| Q34247123 | Reversal of a cholinergic-induced deficit in a rodent model of recognition memory by the selective 5-HT6 receptor antagonist, Ro 04-6790. |
| Q41946578 | Ro 04-6790-induced cognitive enhancement: no effect in trace conditioning and novel object recognition procedures in adult male Wistar rats |
| Q35810041 | Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders |
| Q43279624 | Signalling pathways associated with 5-HT6 receptors: relevance for cognitive effects |
| Q34271590 | The 5-HT6 Receptor Antagonist SB-271046 Reverses Scopolamine-Disrupted Consolidation of a Passive Avoidance Task and Ameliorates Spatial Task Deficits in Aged Rats |
| Q34122424 | The distribution of 5-HT(6) receptors in rat brain: an autoradiographic binding study using the radiolabelled 5-HT(6) receptor antagonist [(125)I]SB-258585. |
| Q33952000 | The pharmacology of headache |
| Q46547641 | The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat. |
| Q28251394 | The serotonin 5-HT6 receptor: a viable drug target for treating cognitive deficits in Alzheimer's disease |
| Q35966817 | Typical and atypical antipsychotic drugs increase extracellular histamine levels in the rat medial prefrontal cortex: contribution of histamine h(1) receptor blockade |